Recent studies have shown that administration of a cannabinoid2 receptor (CB2R) inverse agonist (Wiese et al., 2020) or a brain penetrant cannabinoid1 receptor agonist (CB1R; Wiese et al., 2021) induced respiratory depression (Wiese et al., 2021) – suggesting a tonic role of the CB2R and CB1R in modulation of respiratory functionality. Here, CNR1 is linked to Respiratory insufficiency due to muscle weakness.